PubRank

Effects of Glucagon Administration on Energy Expenditure (GLEE)

Clinical Trial ID NCT02237053

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02237053

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009 7.24
2 Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2011 1.32
3 FGF21-based pharmacotherapy--potential utility for metabolic disorders. Trends Endocrinol Metab 2014 1.29
4 Hormonal control of substrate cycling in humans. J Clin Invest 1988 1.22
5 Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993 1.22
6 Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2012 1.13
7 Effect of glucagon on food intake and body weight in man. J Appl Physiol 1957 1.10
8 The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord 2000 0.94
9 Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab 1987 0.92
10 Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 1994 0.90
11 Insulin dissociates hepatic glucose cycling and glucagon-induced thermogenesis in man. Metabolism 1994 0.89
12 Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo. Am J Physiol 1991 0.84
13 Determinants of sedentary 24-h energy expenditure: equations for energy prescription and adjustment in a respiratory chamber. Am J Clin Nutr 2014 0.79
Next 100